Drug Trial Radar · NCT01190930
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9,350
Actual
Start
Aug 11, 2010
Primary completion
Mar 31, 2019
Study completion Mar 31, 2026
Sponsor
- Lead sponsor
- Children's Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Aug 30, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 year, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This partially randomized phase III trial studies the side effects of different combinations of risk-adapted chemotherapy regimens and how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia or B-lineage lymphoblastic lymphoma that is found only in the tissue or organ where it began (localized). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells.
Conditions
- Acute Lymphoblastic Leukemia
- Adult B Lymphoblastic Lymphoma
- Ann Arbor Stage I B Lymphoblastic Lymphoma
- Ann Arbor Stage II B Lymphoblastic Lymphoma
- Childhood B Acute Lymphoblastic Leukemia
- Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Childhood B Lymphoblastic Lymphoma
- Down Syndrome
- Hypodiploid B Acute Lymphoblastic Leukemia
- Philadelphia Chromosome Positive
Interventions
CyclophosphamideDrug
Given IV
CytarabineDrug
Given IT, IV, or SC
DexamethasoneDrug
Given orally (PO) or IV
Doxorubicin HydrochlorideDrug
Given IV
Laboratory Biomarker AnalysisOther
Correlative studies
Leucovorin CalciumDrug
Given PO
MercaptopurineDrug
Given PO
MethotrexateDrug
Given IT, PO, or IV
PegaspargaseDrug
Given IV
Quality-of-Life AssessmentOther
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
ThioguanineDrug
Given PO
Vincristine SulfateDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose RandomizationTime frame: 5.7 years
- DFS in Average Risk (AR) Patients Based on the Pulse Frequency RandomizationTime frame: 5.7 years
- DFS in Low Risk (LR) Patients Based on Randomization to 1 of 2 Low-intensity RegimensTime frame: 5.1 years
- DFS for SR Down Syndrome Patients With Standardized Treatment and Enhanced Supportive CareTime frame: 5.1 years
- Sample Collection of Central Path Review Slides in B-LLy PatientsTime frame: Up to 1 month
- Event Free Survival (EFS) for B-LLy PatientsTime frame: 5 years
- Overall Survival (OS) for B-LLy PatientsTime frame: 5 years
Locations
243 sites in 7 countries. Site status is shown where the registry gives one.
Children's Hospital of Alabama
Birmingham, Alabama
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
USA Health Strada Patient Care Center
Mobile, Alabama
Providence Alaska Medical Center
Anchorage, Alaska
Banner Children's at Desert
Mesa, Arizona
Phoenix Childrens Hospital
Phoenix, Arizona
Banner University Medical Center - Tucson
Tucson, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Kaiser Permanente Downey Medical Center
Downey, California
City of Hope Comprehensive Cancer Center
Duarte, California
Loma Linda University Medical Center
Loma Linda, California
Miller Children's and Women's Hospital Long Beach
Long Beach, California
Children's Hospital Los Angeles
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
Mattel Children's Hospital UCLA
Los Angeles, California
Valley Children's Hospital
Madera, California
UCSF Benioff Children's Hospital Oakland
Oakland, California
Kaiser Permanente-Oakland
Oakland, California
Children's Hospital of Orange County
Orange, California
Lucile Packard Children's Hospital Stanford University
Palo Alto, California
Sutter Medical Center Sacramento
Sacramento, California
University of California Davis Comprehensive Cancer Center
Sacramento, California
Rady Children's Hospital - San Diego
San Diego, California
Naval Medical Center -San Diego
San Diego, California
UCSF Medical Center-Parnassus
San Francisco, California
UCSF Medical Center-Mission Bay
San Francisco, California
Santa Barbara Cottage Hospital
Santa Barbara, California
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California
Children's Hospital Colorado
Aurora, Colorado
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver, Colorado
Connecticut Children's Medical Center
Hartford, Connecticut
Yale University
New Haven, Connecticut
Alfred I duPont Hospital for Children
Wilmington, Delaware
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Children's National Medical Center
Washington D.C., District of Columbia
Broward Health Medical Center
Fort Lauderdale, Florida
Lee Memorial Health System
Fort Myers, Florida
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida
UF Health Cancer Institute - Gainesville
Gainesville, Florida
Showing 40 of 243 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.